title: Serum Anti-Gal-3 Autoantibody is a Predictive Marker of the Efficacy of Platinum-Based Chemotherapy against Pulmonary Adenocarcinoma.
abstract: BACKGROUND
  Identification of predictive markers for the efficacy of platinum-based chemotherapy is necessary to improve the quality of the life of cancer patients.
  
  
  METHODS
  We detected proteins recognized by autoantibodies in pretreated sera from patients with lung adenocarcinoma (AC) evaluated as showing progressive disease (PD) or a partial response (PR) after cisplatin-based chemotherapy by proteomic analysis. Then, the levels of the candidate autoantibodies in the pretreated serum were validated by dot-blot analysis for 22 AC patients who received platinum-based chemotherapy, and the expression of identified proteins was immunohistochemically analyzed in 40 AC biopsy specimens.
  
  
  RESULTS
  An autoantibody against galectin-3 (Gal-3) was detected in pretreated sera from an AC patient with PD. Serum IgG levels of anti-Gal-3 autoantibody were significantly higher in patients evaluated with PD than in those with PR and stable disease (SD) (p = 0.0084). Furthermore, pretreated biopsy specimens taken from patients evaluated as showing PD following platinum- based chemotherapy showed a tendency to have a higher positive rate of Gal-3 than those with PR and SD (p = 0.0601).
  
  
  CONCLUSIONS
  These results suggest that serum IgG levels of anti-Gal-3 autoantibody may be useful to predict the efficacy of platinum-based chemotherapy for patients with lung AC.
authors.affiliation: Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Kanagawa, Japan E-mail : yuichi@med.kitasato-u.ac.jp.
authors.forename: Kengo
authors.initials: K
authors.lastname: Yanagita
authors.forename: Ryo
authors.initials: R
authors.lastname: Nagashio
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Ryuge
authors.forename: Ken
authors.initials: K
authors.lastname: Katono
authors.forename: Shi-Xu
authors.initials: SX
authors.lastname: Jiang
authors.forename: Benio
authors.initials: B
authors.lastname: Tsuchiya
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Nakashima
authors.forename: Eriko
authors.initials: E
authors.lastname: Fukuda
authors.forename: Naoki
authors.initials: N
authors.lastname: Goshima
authors.forename: Makoto
authors.initials: M
authors.lastname: Saegusa
authors.forename: Yukitoshi
authors.initials: Y
authors.lastname: Satoh
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Masuda
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Sato
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000077192:Adenocarcinoma of Lung; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000097:blood / Q000276:immunology; D001798:Blood Proteins; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000627:therapeutic use*; D037502:Galectin 3 / Q000276:immunology*; D037161:Galectins; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D008175:Lung Neoplasms / Q000188:drug therapy*; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001323:Autoantibodies; D014408:Biomarkers, Tumor; D001798:Blood Proteins; D037502:Galectin 3; D037161:Galectins; D007074:Immunoglobulin G; C428445:LGALS3 protein, human; D002945:Cisplatin